TW202327607A - 用於預防及治療血管栓塞病症之米爾維仙(milvexian) - Google Patents

用於預防及治療血管栓塞病症之米爾維仙(milvexian) Download PDF

Info

Publication number
TW202327607A
TW202327607A TW111135090A TW111135090A TW202327607A TW 202327607 A TW202327607 A TW 202327607A TW 111135090 A TW111135090 A TW 111135090A TW 111135090 A TW111135090 A TW 111135090A TW 202327607 A TW202327607 A TW 202327607A
Authority
TW
Taiwan
Prior art keywords
milvecin
daily dose
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Application number
TW111135090A
Other languages
English (en)
Chinese (zh)
Inventor
約翰 史壯尼
蓋瑞 彼得斯
馬伍 錢塔勒
克里斯多福 納賽爾
利亞納蓋 威德亞 培瑞拉
丹石 李
喬瑟夫 Ｍ 呂特根
迪特馬 阿爾弗雷德 賽伏特
伯頓 夏洛特 瓊斯
Original Assignee
美商必治妥美雅史谷比公司
比利時商健生藥品公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商必治妥美雅史谷比公司, 比利時商健生藥品公司 filed Critical 美商必治妥美雅史谷比公司
Publication of TW202327607A publication Critical patent/TW202327607A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111135090A 2021-09-17 2022-09-16 用於預防及治療血管栓塞病症之米爾維仙(milvexian) TW202327607A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163245522P 2021-09-17 2021-09-17
US63/245,522 2021-09-17
US202163278582P 2021-11-12 2021-11-12
US63/278,582 2021-11-12

Publications (1)

Publication Number Publication Date
TW202327607A true TW202327607A (zh) 2023-07-16

Family

ID=83688923

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111135090A TW202327607A (zh) 2021-09-17 2022-09-16 用於預防及治療血管栓塞病症之米爾維仙(milvexian)

Country Status (11)

Country Link
US (1) US20250099466A1 (https=)
EP (1) EP4401736A1 (https=)
JP (1) JP2024534427A (https=)
KR (1) KR20240060820A (https=)
AU (1) AU2022345862A1 (https=)
CA (1) CA3232633A1 (https=)
CL (1) CL2024000776A1 (https=)
IL (1) IL310894A (https=)
MX (1) MX2024002857A (https=)
TW (1) TW202327607A (https=)
WO (1) WO2023043999A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA71692A (fr) * 2022-08-01 2025-05-30 Bristol-Myers Squibb Company Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique
TW202506125A (zh) * 2023-04-19 2025-02-16 美商必治妥美雅史谷比公司 米爾維仙(milvexian)於治療及預防患有心血管或腦血管疾病之患者之血栓病況的用途
WO2024220803A1 (en) * 2023-04-19 2024-10-24 Bristol-Myers Squibb Company Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation
EP4698172A1 (en) * 2023-04-19 2026-02-25 Bristol-Myers Squibb Company Use of milvexian for treating or preventing adverse cerebrovascular events or adverse cardiovascular events in patients having acute coronary syndrome
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
BR112021020257A2 (pt) 2019-04-11 2021-12-07 Bristol Myers Squibb Co Desempenho intensificado de sólido amorfo e formulações solubilizadas para realizar concentrações de plasma terapêutico

Also Published As

Publication number Publication date
CL2024000776A1 (es) 2024-07-26
AU2022345862A1 (en) 2024-03-14
IL310894A (en) 2024-04-01
JP2024534427A (ja) 2024-09-20
KR20240060820A (ko) 2024-05-08
EP4401736A1 (en) 2024-07-24
CA3232633A1 (en) 2023-03-23
US20250099466A1 (en) 2025-03-27
WO2023043999A1 (en) 2023-03-23
MX2024002857A (es) 2024-03-21

Similar Documents

Publication Publication Date Title
TW202327607A (zh) 用於預防及治療血管栓塞病症之米爾維仙(milvexian)
JP5792059B2 (ja) 抗血小板療法中の血小板抑制のメンテナンス
JP2023507153A (ja) 筋萎縮性側索硬化症及び関連する疾患の治療
US10688075B2 (en) Method of treating patients with a factor Xa inhibitor, aspirin, and verapamil
TW201031651A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
KR20110104491A (ko) 활성화 혈액 응고 제 Ｘ 인자 (ＦＸａ) 저해제
KR20240116816A (ko) 진행성 섬유화 간질성 폐질환 치료를 위한 새로운 치료제 병용물
AU2025205402A1 (en) New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases
RS62797B1 (sr) Postupak tretmana pacijenata zajedničkom primenom rivaroksabana i verapamila
Khatri et al. Management of coronary chronic total occlusion
JP6840197B2 (ja) 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
CN118302166A (zh) 用于预防及治疗血管栓塞病症的米尔维仙
US20250195549A1 (en) New use
CA2993858A1 (en) Combination of rivaroxaban and acetylsalicylic acid for reducing the risk of cardiovascular events
EP4593833A1 (en) Fractalkine receptor antagonists for use in the prevention of thrombus formation and/or growth
WO2025133022A1 (en) Fractalkine receptor antagonists for use in the prevention of thrombus formation and/or growth
MXPA04001174A (es) Tratamiento para lipodistrofia.
Rahman A clinically oriented review of the landmark clinical trials comparing warfarin and aspirin to novel oral anticoagulants in atrial fibrillation
CN118369098A (zh) 用于治疗进行性纤维化间质性肺病的新颖治疗组合
Turpie Oral Direct Factor Xa Inhibitors
TW200409638A (en) Use of MELOXICAM in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions